Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A/T/S vs BIPHETAMINE 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
Treatment of acne vulgaris (FDA-approved indication),Treatment of bacterial infections caused by susceptible organisms (off-label use for acne is the primary use)
Narcolepsy,Attention Deficit Hyperactivity Disorder (ADHD) (FDA-approved for these indications as a schedule II controlled substance)
Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
Terminal elimination half-life: 1–2 hours (prolonged in hepatic impairment).
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
Antithrombin is a glycoprotein; its metabolism involves cellular uptake and catabolism, but specific CYP450 enzymes are not involved. Degradation occurs via proteolysis and reticuloendothelial system clearance.
Metabolized primarily by the liver via CYP2D6 and to a lesser extent by CYP3A4. Major metabolic pathways include hydroxylation, deamination, and oxidation to benzoic acid derivatives. Excretion is primarily renal.
Renal: 10-20% (active drug and metabolites); Fecal: minimal; Biliary: not significant.
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
70-90% bound to serum albumin.
16–20% (primarily to albumin)
0.5–0.8 L/kg (low Vd, minimal tissue penetration).
3–4 L/kg; indicates extensive tissue distribution
Topical: 1–5% (minimal systemic absorption).
Oral: 75–100% (first-pass metabolism minimal)
No specific adjustment required; drug is not renally eliminated.
e GFR <30 m L/min: contraindicated; e GFR 30-59 m L/min: use with caution, reduce dose by 50%.
No specific adjustment; antithrombin is produced in the liver, but exogenous replacement does not require dose adjustment in hepatic impairment.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use not recommended.
Dosing based on weight and antithrombin levels; typical initial dose 30-50 IU/kg, followed by maintenance to achieve target levels. Clinical trial data limited in neonates.
Children ≥6 years: initial 5 mg orally once daily; titrate by 5 mg weekly to max 20 mg/day.
No specific adjustment; use standard dosing with monitoring of antithrombin activity and bleeding risk.
Initiate at 5 mg orally once daily; increase slowly with monitoring for cardiovascular effects.
None.
WARNING: ABUSE AND DEPENDENCE. Biphetamine contains amphetamine and dextroamphetamine, which have a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Hypersensitivity reactions including anaphylaxis have occurred.,Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Use with caution in patients with hepatic impairment.,Potential for QT prolongation and ventricular arrhythmias, especially with intravenous administration or concomitant drugs that prolong QT interval.
Cardiovascular: risk of sudden death or serious cardiovascular events, especially in patients with pre-existing cardiac abnormalities.,CNS effects: may cause psychotic or manic symptoms, aggression, seizures, and visual disturbances.,Growth suppression: may cause weight loss and growth retardation in children.,Peripheral vasculopathy: including Raynaud's phenomenon.,Serotonin syndrome: when co-administered with serotonergic drugs.,Potential for immediate hypersensitivity reactions.
Hypersensitivity to erythromycin or any macrolide antibiotic.,Use with caution in patients with pre-existing QT prolongation or electrolyte abnormalities (relative contraindication).
Hypersensitivity to amphetamine or dextroamphetamine,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis risk),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (e.g., advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension),Motor tics or Tourette's syndrome (worsening possible)
No specific food interactions. Avoid excessive alcohol consumption as it may increase skin dryness.
Avoid foods and beverages high in caffeine or other stimulants (e.g., coffee, tea, cola, chocolate) as they may increase stimulant effects and risk of adverse reactions. Acidic foods (e.g., citrus fruits, juices) and vitamin C can decrease absorption; separate intake by at least 1 hour. Maintain a consistent meal schedule to minimize appetite suppression.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk to fetus is low across all trimesters.
First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth weight, neonatal withdrawal syndrome, and potential for behavioral effects. Avoid use unless benefit outweighs risk.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Topical use results in negligible systemic exposure; unlikely to cause adverse effects in nursing infants.
Contraindicated in breastfeeding. Amphetamines are excreted in human milk (M/P ratio not established) and may cause infant agitation, poor feeding, and growth suppression. Discontinue drug or nursing.
No dose adjustment required. Systemic absorption from topical application is minimal and not significantly altered by pregnancy-related pharmacokinetic changes.
No established dosage adjustments in pregnancy; use lowest effective dose for shortest duration. Increased clearance during pregnancy may require dose increase, but safety data insufficient. Avoid in pregnancy unless essential.
A/T/S (erythromycin 2% topical solution) is indicated for acne vulgaris. Avoid contact with eyes, mouth, and mucous membranes. May cause skin dryness or irritation; use moisturizer. Effectiveness may decrease with prolonged use due to bacterial resistance. Not recommended for use with other topical erythromycin products or clindamycin to avoid antagonism.
Monitor for hypertension and tachycardia; avoid use in patients with cardiovascular disease, hyperthyroidism, or glaucoma. Use with caution in patients with a history of substance abuse. May exacerbate tics and Tourette syndrome. Do not administer late in the day due to insomnia risk. Discontinue if seizures occur.
Apply a thin layer to affected areas twice daily after washing.,Avoid contact with eyes, lips, and mouth; if contact occurs, rinse thoroughly with water.,May cause stinging, burning, or peeling; if irritation persists, consult your doctor.,Use sunscreen daily as this medication may increase sensitivity to sunlight.,Do not use more than prescribed; overuse may increase side effects without improving results.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep away from open flames or heat sources; product is flammable.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose upon awakening; avoid taking late in the day to prevent sleep problems.,Do not chew or crush tablets; swallow whole with water.,Avoid alcohol and caffeine while taking this medication.,Report any chest pain, palpitations, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A/T/S vs BIPHETAMINE 20, answered by our medical review team.
A/T/S is a Macrolide antibiotic that works by A/T/S (erythromycin) is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.. BIPHETAMINE 20 is a Central Nervous System Stimulant that works by Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A/T/S and BIPHETAMINE 20 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A/T/S is: Dosing is individualized based on antithrombin activity level. For acute thrombotic events: initial bolus of 30-50 IU/kg followed by maintenance dosing to achieve target activity levels (80-120% of normal). Prophylaxis: 40-60 IU/kg every 24 hours.. The standard adult dose of BIPHETAMINE 20 is: 10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A/T/S and BIPHETAMINE 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A/T/S is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Topical erythromycin has minimal systemic absorption; risk . BIPHETAMINE 20 is classified as Category C. First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.